RLFTF (Relief Therapeutics Holding) Common Stock: $1.73 Mil (As of Jun. 2025)


RLFTF Relief Therapeutics Holding SA RLFTF
31 GF Score
Price $0.26
GF Value $0.58
! 5 Warning Signs
View Full Analysis

What is Relief Therapeutics Holding Common Stock?

Relief Therapeutics Holding RLFTF 31 Common Stock is $1.73 Mil as of Jun. 2025. GuruFocus rates RLFTF with a GF Score™ of 31/100 and a GF Value™ of $0.58. The stock has 5 warning signs investors should review.

Relief Therapeutics Holding's quarterly common stock increased from Jun. 2024 ($1.57 Mil) to Dec. 2024 ($1.58 Mil) and increased from Dec. 2024 ($1.58 Mil) to Jun. 2025 ($1.73 Mil).

Relief Therapeutics Holding's annual common stock increased from Dec. 2022 ($60.29 Mil) to Dec. 2023 ($64.94 Mil) but then declined from Dec. 2023 ($64.94 Mil) to Dec. 2024 ($1.58 Mil).

Relief Therapeutics Holding Common Stock Historical Data

* Premium members only.

The historical data trend for Relief Therapeutics Holding's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relief Therapeutics Holding Common Stock Chart

Relief Therapeutics Holding Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.55 47.92 60.29 64.94 1.58

Relief Therapeutics Holding Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.38 64.94 1.57 1.58 1.73
RLFTF
31GF Score
Relief Therapeutics Holding SA RLFTF
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relief Therapeutics Holding Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $1.73 Mil mean?
Relief Therapeutics Holding (RLFTF) has a Common Stock of $1.73 Mil as of Jun. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Relief Therapeutics Holding and its competitors.
Is Relief Therapeutics Holding's Common Stock too high?
Relief Therapeutics Holding's current Common Stock is $1.73 Mil. Overall, Relief Therapeutics Holding has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Common Stock compare to KTTA and OSRH?
Relief Therapeutics Holding's Common Stock of $1.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current Common Stock is $1.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (RLFTF) has a current Common Stock of $1.73 Mil. The stock's GF Value™ is $0.58, compared to a current price of $0.26 — trading 54.8% below its estimated fair value. The current Common Stock is $1.73 Mil. Relief Therapeutics Holding's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Relief Therapeutics Holding (RLFTF), the current Common Stock is $1.73 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relief Therapeutics Holding (RLFTF) Overvalued in 2026?

Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued. The current stock price of $0.26 is trading 54.8% below its estimated GF Value™ of $0.58.

Key valuation signals for RLFTF:

  • Common Stock: $1.73 Mil
  • GF Value™: $0.58 vs. price of $0.26 (54.8% below fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the RLFTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Relief Therapeutics Holding Business Description

Address Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
31GF Score

Get the complete analysis for RLFTF

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.26
Price
$0.58
GF Value